[ad_1]
- ATG-017 is an oral small molecule ERK1/2 inhibitor; Odiwo® Is aPD-1 checkpoint inhibitor
- Combination research will start at H12022
Shanghai and Hongkong, December 12, 2021 /PRNewswire/ – Antengene Corporation Limited (“Antengene” SEHK: 6996.HK) is a leading innovative global biopharmaceutical company dedicated to the discovery, development and commercialization of first-class and/or first-class cancers and/or cancers drug.Other life-threatening diseases, announced today A clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of the combination of ATG-017 and Bristol-Myers Squibb’s PD-1 checkpoint inhibitor Opdivo® (Nivolumab).The open-label Phase 1/2 trial will evaluate the study portfolio as a potential treatment option for patients with advanced solid tumors.
“Our clinical collaboration with Bristol Myers Squibb underscores Antengene’s commitment to exploring joint solutions in our product portfolio and other mechanisms of action that may change cancer care,” said Jermaine, MD, Ph.D., Founder and CEO of Antengene. “We are very pleased to have this clinical collaboration with Bristol Myers Squibb and look forward to registering for this exciting joint program in the first half of 2022.”
ATG-017 is an oral selective inhibitor of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2). Odiwo® It is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor expressed on activated T cells. This collaboration builds on Antengene’s pre-clinical data sets, some of which have been announced at the Society for Cancer Immunotherapy (SITC) in 2021This indicates that the combination of ERK1/2 inhibitors and immune checkpoint inhibitors (CPI) work synergistically to produce better efficacy in preclinical immune CPI-resistant cancer models.
“Antengene believes that a reasonable combination of targeted therapy and immuno-oncology drugs may provide the greatest chance of success for the next advancement in cancer treatment,” said Kevin Lynch, MD, Chief Medical Officer of Antengene. “We believe that ATG-017 can be used in a variety of combinations. In preclinical studies,…
The full story can be found on Benzinga.com
[ad_2]
Source link
